[ad_1]
Fourteen percent of volunteers vaccinated with the Sputnik V vaccine, developed to prevent a new type of coronavirus infection, or about one in seven people, experienced weakness, fever or muscle pain that lasted a day and a half, the minister said. Minister of Health Mikhail Murasko to reporters in Moscow on Tuesday. In the third phase of clinical trials, 300 people have been vaccinated so far.
Murasko called the symptoms a predictable complication. He recalled that the first Russian vaccine had been developed on an adenovirus platform that had already been used for other vaccines and had been shown to be safe. At the same time, he himself stressed the importance of thorough testing.
Sputnik V is produced in parallel by three large companies, as scheduled. The Lancet published the results of the first and second phases of the tests on September 4. The study found that vaccinated people developed about one and a half times more antibodies than those who had suffered from Covid-19 disease.
Regarding the current test, Moscow Deputy Mayor Anastasia Rakova said that volunteers are being monitored from a telemedicine center using a phone app or a digital bracelet to make video calls and enter health data.
Medical Director Anna Popova, head of Russia’s Consumer Protection Inspectorate (Rospotrebnadzor), told a meeting at the Russian Academy of Sciences on Tuesday that 17 institutes in Russia are currently working on the development of 26 vaccines against Covid- 19.
Other concerns have been identified that have yet to be identified in the current trial, which consider that the current trial results are insufficient to assess the safety of the vaccine. According to Tamás Letoha, a researcher at Szeged, the adeno-associated viruses (AAVs) that form the basis of the Russian vaccine are non-human pathogens that can enter the cells of the human body with high efficiency and contribute to the expression of any gene there. Since AAVs can also be incorporated into human inheritance, they can alter the normal functioning of certain human genes, thus incorporating the development of tumor processes.
It is no coincidence that pharmaceutical companies around the world, while having the high-level technological skills necessary to develop AAV-based therapies, are cautious about the use of AAV-based coronavirus vaccines. And the effects of mutations caused by AAVs will only become apparent in the next few years, and this potential side effect may appear regardless of the immunity it targets, the researcher explained on his Facebook page.
[ad_2]
